| NCT03410901 |
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03410901 |
Recruiting |
Stanford University |
2020-10-09 |
| NCT03323151 |
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03323151 |
Recruiting |
PrECOG, LLC. |
2024-01-31 |
| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
https://ClinicalTrials.gov/show/NCT03314974 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2025-01-10 |
| NCT03311126 |
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03311126 |
Recruiting |
University of Wisconsin, Madison |
2024-05-15 |
| NCT03295240 |
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03295240 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-20 |
| NCT03282396 |
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03282396 |
Recruiting |
M.D. Anderson Cancer Center |
2022-02-28 |
| NCT03277729 |
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03277729 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-11-16 |
| NCT03267433 |
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission |
https://ClinicalTrials.gov/show/NCT03267433 |
Recruiting |
Eastern Cooperative Oncology Group |
2027-01-31 |
| NCT03246906 |
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03246906 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-08-15 |
| NCT03235544 |
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) |
https://ClinicalTrials.gov/show/NCT03235544 |
Recruiting |
Incyte Corporation |
2020-07-31 |
| NCT03229382 |
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell |
https://ClinicalTrials.gov/show/NCT03229382 |
Recruiting |
Polish Lymphoma Research Group |
2023-07-31 |
| NCT03219047 |
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03219047 |
Recruiting |
M.D. Anderson Cancer Center |
2020-09-30 |
| NCT03206970 |
Study of Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT03206970 |
Active, not recruiting |
BeiGene |
2019-02-15 |
| NCT03190330 |
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion |
https://ClinicalTrials.gov/show/NCT03190330 |
Recruiting |
Johnson & Johnson Private Limited |
2021-09-29 |
| NCT03162536 |
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03162536 |
Recruiting |
ArQule |
2021-12-31 |
| NCT03153202 |
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT03153202 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2021-04-10 |
| NCT03151057 |
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies |
https://ClinicalTrials.gov/show/NCT03151057 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-09-30 |
| NCT03128359 |
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03128359 |
Recruiting |
City of Hope Medical Center |
2021-01-31 |
| NCT03097770 |
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 |
https://ClinicalTrials.gov/show/NCT03097770 |
Recruiting |
Chinese PLA General Hospital |
2019-05-10 |
| NCT03037645 |
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers |
https://ClinicalTrials.gov/show/NCT03037645 |
Recruiting |
Sunesis Pharmaceuticals |
2020-12-31 |
| NCT03035331 |
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03035331 |
Recruiting |
Mayo Clinic |
2021-02-15 |
| NCT03028103 |
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients |
https://ClinicalTrials.gov/show/NCT03028103 |
Active, not recruiting |
Epizyme, Inc. |
2019-10-31 |
| NCT03019666 |
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
https://ClinicalTrials.gov/show/NCT03019666 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-09-30 |
| NCT03019640 |
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03019640 |
Recruiting |
M.D. Anderson Cancer Center |
2020-03-31 |
| NCT03015896 |
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03015896 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-04-30 |
| NCT03010982 |
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors |
https://ClinicalTrials.gov/show/NCT03010982 |
Completed |
Epizyme, Inc. |
2019-01-08 |
| NCT03010358 |
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03010358 |
Active, not recruiting |
OHSU Knight Cancer Institute |
2022-02-28 |
| NCT02996773 |
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine |
https://ClinicalTrials.gov/show/NCT02996773 |
Recruiting |
University of Arizona |
2022-11-29 |
| NCT02991638 |
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers |
https://ClinicalTrials.gov/show/NCT02991638 |
Recruiting |
The University of Hong Kong |
2020-12-31 |
| NCT02972840 |
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02972840 |
Recruiting |
Acerta Pharma BV |
2022-10-31 |
| NCT02952508 |
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) |
https://ClinicalTrials.gov/show/NCT02952508 |
Recruiting |
Cellectar Biosciences, Inc. |
2020-07-31 |
| NCT02950220 |
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02950220 |
Completed |
Ohio State University Comprehensive Cancer Center |
2018-11-19 |
| NCT02914938 |
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02914938 |
Recruiting |
MEI Pharma, Inc. |
2021-09-30 |
| NCT02896582 |
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance |
https://ClinicalTrials.gov/show/NCT02896582 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2019-03-31 |
| NCT02869633 |
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02869633 |
Active, not recruiting |
Vanderbilt-Ingram Cancer Center |
2021-10-31 |
| NCT02858258 |
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02858258 |
Recruiting |
European Mantle Cell Lymphoma Network |
2021-05-31 |
| NCT02825836 |
BTK Inhibitor in B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT02825836 |
Active, not recruiting |
EMD Serono |
2021-09-01 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02756247 |
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma |
https://ClinicalTrials.gov/show/NCT02756247 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT02745769 |
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents |
https://ClinicalTrials.gov/show/NCT02745769 |
Completed |
Eli Lilly and Company |
2018-11-05 |
| NCT02736617 |
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02736617 |
Recruiting |
OHSU Knight Cancer Institute |
2022-12-01 |
| NCT02728531 |
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02728531 |
Active, not recruiting |
Washington University School of Medicine |
2019-01-16 |
| NCT02722668 |
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
https://ClinicalTrials.gov/show/NCT02722668 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2028-05-31 |
| NCT02717624 |
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL |
https://ClinicalTrials.gov/show/NCT02717624 |
Recruiting |
Acerta Pharma BV |
2026-05-31 |
| NCT02682641 |
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL |
https://ClinicalTrials.gov/show/NCT02682641 |
Active, not recruiting |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2019-12-31 |
| NCT02669017 |
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) |
https://ClinicalTrials.gov/show/NCT02669017 |
Completed |
ADC Therapeutics S.A. |
2019-02-21 |
| NCT02661035 |
Allo HSCT Using RIC for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT02661035 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-03-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02650999 |
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas |
https://ClinicalTrials.gov/show/NCT02650999 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2019-02-25 |
| NCT02633137 |
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02633137 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT02632396 |
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission |
https://ClinicalTrials.gov/show/NCT02632396 |
Recruiting |
Emory University |
2021-04-30 |
| NCT02631044 |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) |
https://ClinicalTrials.gov/show/NCT02631044 |
Recruiting |
Juno Therapeutics, a Subsidiary of Celgene |
2022-12-31 |
| NCT02603445 |
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL |
https://ClinicalTrials.gov/show/NCT02603445 |
Completed |
Novartis |
2018-07-10 |
| NCT01028716 |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01028716 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2024-01-04 |
| NCT03112174 |
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) |
https://ClinicalTrials.gov/show/NCT03112174 |
Recruiting |
Pharmacyclics LLC. |
2022-03-31 |
| NCT03088878 |
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT03088878 |
Recruiting |
University of California, San Diego |
2020-10-01 |
| NCT02927964 |
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02927964 |
Recruiting |
Stanford University |
2021-11-30 |
| NCT02793583 |
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT02793583 |
Recruiting |
TG Therapeutics, Inc. |
2021-05-31 |
| NCT02572453 |
Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02572453 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-10-01 |
| NCT04116437 |
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment |
https://ClinicalTrials.gov/show/NCT04116437 |
Recruiting |
BeiGene |
2022-09-30 |
| NCT02568553 |
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02568553 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT00101101 |
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00101101 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2012-10-31 |
| NCT00005780 |
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00005780 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2005-08-31 |
| NCT02558816 |
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02558816 |
Active, not recruiting |
Nantes University Hospital |
2019-04-30 |
| NCT01381692 |
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01381692 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-07-23 |
| NCT02507336 |
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 |
https://ClinicalTrials.gov/show/NCT02507336 |
Active, not recruiting |
University of Miami |
2020-11-30 |
| NCT02494700 |
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02494700 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT02489123 |
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02489123 |
Active, not recruiting |
University of Washington |
2023-07-01 |
| NCT02483000 |
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT02483000 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2019-11-17 |
| NCT02460276 |
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02460276 |
Completed |
Lund University Hospital |
2019-12-31 |
| NCT02446236 |
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02446236 |
Active, not recruiting |
Hackensack Meridian Health |
2022-12-31 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02427620 |
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02427620 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-06-30 |
| NCT02420795 |
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02420795 |
Recruiting |
M.D. Anderson Cancer Center |
2021-11-01 |
| NCT02356458 |
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02356458 |
Active, not recruiting |
Swiss Group for Clinical Cancer Research |
2021-03-31 |
| NCT02339922 |
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02339922 |
Active, not recruiting |
University of Washington |
2025-01-06 |
| NCT02278796 |
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) |
https://ClinicalTrials.gov/show/NCT02278796 |
Active, not recruiting |
University Hospital Inselspital, Berne |
2018-11-28 |
| NCT02268851 |
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL |
https://ClinicalTrials.gov/show/NCT02268851 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2018-05-31 |
| NCT02267915 |
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT |
https://ClinicalTrials.gov/show/NCT02267915 |
Active, not recruiting |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2019-12-31 |
| NCT02257242 |
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02257242 |
Recruiting |
Brown University |
2020-12-31 |
| NCT02242097 |
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02242097 |
Active, not recruiting |
Northwestern University |
2022-06-30 |
| NCT02240719 |
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT02240719 |
Completed |
University of California, Davis |
2018-04-09 |
| NCT02216890 |
Safety Study of SGN-CD70A in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02216890 |
Completed |
Seattle Genetics, Inc. |
2017-02-15 |
| NCT02213926 |
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02213926 |
Active, not recruiting |
Acerta Pharma BV |
2017-02-28 |
| NCT02213913 |
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02213913 |
Recruiting |
University of Chicago |
2020-07-29 |
| NCT02169180 |
Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02169180 |
Completed |
Janssen Pharmaceutical K.K. |
2016-11-30 |
| NCT02159755 |
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02159755 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-06-25 |
| NCT02153580 |
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02153580 |
Recruiting |
City of Hope Medical Center |
2021-12-31 |
| NCT02142530 |
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL |
https://ClinicalTrials.gov/show/NCT02142530 |
Completed |
Massachusetts General Hospital |
2017-03-31 |
| NCT01318317 |
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01318317 |
Active, not recruiting |
City of Hope Medical Center |
2022-08-31 |
| NCT01314014 |
Imexon for Relapsed Follicular and Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT01314014 |
Completed |
University of Rochester |
2013-03-31 |
| NCT01300026 |
AMG 319 Lymphoid Malignancy FIH |
https://ClinicalTrials.gov/show/NCT01300026 |
Completed |
Amgen |
2013-10-31 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02051257 |
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02051257 |
Active, not recruiting |
City of Hope Medical Center |
2021-06-30 |
| NCT02049541 |
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02049541 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2018-09-12 |
| NCT03932331 |
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies |
https://ClinicalTrials.gov/show/NCT03932331 |
Recruiting |
AstraZeneca |
2022-03-25 |
| NCT00088205 |
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00088205 |
Completed |
Eli Lilly and Company |
2008-05-31 |
| NCT04234061 |
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04234061 |
Recruiting |
Peter MacCallum Cancer Centre, Australia |
2027-09-01 |
| NCT03479268 |
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03479268 |
Recruiting |
City of Hope Medical Center |
2022-04-01 |
| NCT03329950 |
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03329950 |
Recruiting |
Celldex Therapeutics |
2021-08-31 |
| NCT02013128 |
Ublituximab + Ibrutinib in Select B-cell Malignancies |
https://ClinicalTrials.gov/show/NCT02013128 |
Completed |
TG Therapeutics, Inc. |
2015-12-31 |
| NCT01996865 |
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. |
https://ClinicalTrials.gov/show/NCT01996865 |
Active, not recruiting |
Celgene |
2023-04-08 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01955499 |
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01955499 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT01921387 |
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01921387 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2017-07-26 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01880567 |
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01880567 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-31 |
| NCT01865617 |
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT01865617 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2034-04-02 |
| NCT01865110 |
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL |
https://ClinicalTrials.gov/show/NCT01865110 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2021-06-30 |
| NCT01851551 |
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL |
https://ClinicalTrials.gov/show/NCT01851551 |
Completed |
Acrotech Biopharma LLC |
2004-04-30 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01838434 |
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01838434 |
Completed |
Alliance for Clinical Trials in Oncology |
2014-09-30 |
| NCT01815749 |
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01815749 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01804686 |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
https://ClinicalTrials.gov/show/NCT01804686 |
Enrolling by invitation |
Janssen Research & Development, LLC |
2026-12-31 |
| NCT01799889 |
Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01799889 |
Completed |
Gilead Sciences |
2017-09-14 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01786135 |
A Safety Study of SGN-CD19A for B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01786135 |
Completed |
Seattle Genetics, Inc. |
2015-08-31 |
| NCT01776840 |
A Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01776840 |
Active, not recruiting |
Janssen Research & Development, LLC |
2021-06-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01744912 |
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01744912 |
Completed |
TG Therapeutics, Inc. |
2014-05-31 |
| NCT01739309 |
Study of LY2835219 for Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01739309 |
Active, not recruiting |
Eli Lilly and Company |
2015-09-28 |
| NCT01737177 |
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL |
https://ClinicalTrials.gov/show/NCT01737177 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2014-07-31 |
| NCT01719250 |
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01719250 |
Completed |
Mayo Clinic |
2016-09-16 |
| NCT01718691 |
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01718691 |
Completed |
SymBio Pharmaceuticals |
2013-11-30 |
| NCT01695941 |
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01695941 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-05-29 |
| NCT01693614 |
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL |
https://ClinicalTrials.gov/show/NCT01693614 |
Completed |
Novartis |
2017-07-21 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01665768 |
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma |
https://ClinicalTrials.gov/show/NCT01665768 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2017-10-31 |
| NCT01662050 |
Phase II Study of Ageâ€Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL |
https://ClinicalTrials.gov/show/NCT01662050 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2012-08-31 |
| NCT01661881 |
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01661881 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2015-02-28 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01652144 |
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01652144 |
Completed |
Canadian Cancer Trials Group |
2014-12-02 |
| NCT01646021 |
Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy |
https://ClinicalTrials.gov/show/NCT01646021 |
Completed |
Janssen Research & Development, LLC |
2015-06-05 |
| NCT01599949 |
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy |
https://ClinicalTrials.gov/show/NCT01599949 |
Completed |
Janssen Research & Development, LLC |
2015-05-31 |
| NCT01597778 |
Double Cord Versus Haploidentical (BMT CTN 1101) |
https://ClinicalTrials.gov/show/NCT01597778 |
Active, not recruiting |
Medical College of Wisconsin |
2020-06-30 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01562977 |
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL |
https://ClinicalTrials.gov/show/NCT01562977 |
Completed |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2015-04-30 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01527149 |
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01527149 |
Active, not recruiting |
Roswell Park Cancer Institute |
2018-04-26 |
| NCT01527045 |
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01527045 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-10-31 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01504776 |
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT01504776 |
Completed |
Augusta University |
2014-09-30 |
| NCT01484093 |
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01484093 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01479842 |
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01479842 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2014-03-31 |
| NCT01475058 |
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant |
https://ClinicalTrials.gov/show/NCT01475058 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-04-30 |
| NCT01472562 |
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01472562 |
Active, not recruiting |
Weill Medical College of Cornell University |
2014-04-30 |
| NCT01460134 |
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01460134 |
Completed |
Celldex Therapeutics |
2015-12-31 |
| NCT01457144 |
Study of Mantle Cell Lymphoma Treatment by RiBVD |
https://ClinicalTrials.gov/show/NCT01457144 |
Completed |
French Innovative Leukemia Organisation |
2014-09-30 |
| NCT01456351 |
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab |
https://ClinicalTrials.gov/show/NCT01456351 |
Completed |
University of Giessen |
2010-08-31 |
| NCT01439750 |
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) |
https://ClinicalTrials.gov/show/NCT01439750 |
Active, not recruiting |
Milton S. Hershey Medical Center |
2018-08-31 |
| NCT01437709 |
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01437709 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-09-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01415752 |
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01415752 |
Active, not recruiting |
Eastern Cooperative Oncology Group |
2020-03-31 |
| NCT01412879 |
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01412879 |
Active, not recruiting |
Southwest Oncology Group |
2016-02-29 |
| NCT01410513 |
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01410513 |
Completed |
Sanofi |
2014-05-31 |
| NCT01399840 |
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01399840 |
Completed |
Pfizer |
2014-03-31 |
| NCT01397825 |
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine |
https://ClinicalTrials.gov/show/NCT01397825 |
Completed |
Takeda |
2015-02-05 |
| NCT01389427 |
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). |
https://ClinicalTrials.gov/show/NCT01389427 |
Completed |
The Lymphoma Academic Research Organisation |
2015-05-31 |
| NCT01345357 |
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01345357 |
Completed |
Teva Pharmaceutical Industries |
2012-12-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04323657 |
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT04323657 |
Recruiting |
TCR2 Therapeutics |
2022-04-30 |
| NCT04282018 |
Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab |
https://ClinicalTrials.gov/show/NCT04282018 |
Recruiting |
BeiGene |
2025-03-26 |
| NCT04231734 |
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04231734 |
Recruiting |
Weill Medical College of Cornell University |
2021-12-31 |
| NCT04191187 |
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04191187 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-12-31 |
| NCT04186520 |
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT04186520 |
Recruiting |
Medical College of Wisconsin |
2023-05-01 |
| NCT04184414 |
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT04184414 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2020-01-01 |
| NCT04176913 |
Study of LUCAR-20S in Patients With R/R NHL |
https://ClinicalTrials.gov/show/NCT04176913 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2022-10-22 |
| NCT04115631 |
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04115631 |
Recruiting |
Eastern Cooperative Oncology Group |
2024-03-31 |
| NCT04082936 |
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04082936 |
Recruiting |
IGM Biosciences, Inc. |
2021-09-30 |
| NCT04054167 |
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04054167 |
Recruiting |
M.D. Anderson Cancer Center |
2021-05-29 |
| NCT04049513 |
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) |
https://ClinicalTrials.gov/show/NCT04049513 |
Recruiting |
Malaghan Institute of Medical Research |
2021-09-30 |
| NCT04047797 |
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04047797 |
Recruiting |
M.D. Anderson Cancer Center |
2022-06-01 |
| NCT04014205 |
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT04014205 |
Recruiting |
Beijing InnoCare Pharma Tech Co., Ltd. |
2020-08-17 |
| NCT04007029 |
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT04007029 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2022-08-01 |
| NCT04002297 |
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04002297 |
Recruiting |
BeiGene |
2021-07-31 |
| NCT03999697 |
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT03999697 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2020-12-01 |
| NCT03997968 |
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03997968 |
Recruiting |
Cyteir Therapeutics, Inc. |
2021-09-30 |
| NCT03946878 |
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03946878 |
Recruiting |
M.D. Anderson Cancer Center |
2024-02-08 |
| NCT03939182 |
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03939182 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT03891355 |
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL |
https://ClinicalTrials.gov/show/NCT03891355 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2020-04-30 |
| NCT03886831 |
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03886831 |
Recruiting |
Prelude Therapeutics |
2021-08-11 |
| NCT03877055 |
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03877055 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT03863184 |
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL |
https://ClinicalTrials.gov/show/NCT03863184 |
Recruiting |
Weill Medical College of Cornell University |
2022-11-01 |
| NCT03842696 |
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT03842696 |
Recruiting |
University of Michigan Rogel Cancer Center |
2024-02-29 |
| NCT03836768 |
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03836768 |
Active, not recruiting |
Zhejiang DTRM Biopharma |
2021-09-30 |
| NCT03834688 |
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age |
https://ClinicalTrials.gov/show/NCT03834688 |
Recruiting |
PrECOG, LLC. |
2022-03-31 |
| NCT03833180 |
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03833180 |
Recruiting |
VelosBio Inc. |
2021-03-31 |
| NCT03740529 |
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL |
https://ClinicalTrials.gov/show/NCT03740529 |
Recruiting |
Loxo Oncology, Inc. |
2020-10-31 |
| NCT03710772 |
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03710772 |
Recruiting |
M.D. Anderson Cancer Center |
2021-04-22 |
| NCT03685344 |
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03685344 |
Active, not recruiting |
ADC Therapeutics S.A. |
2021-01-29 |
| NCT03684694 |
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03684694 |
Recruiting |
ADC Therapeutics S.A. |
2022-04-15 |
| NCT03676504 |
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR |
https://ClinicalTrials.gov/show/NCT03676504 |
Recruiting |
University Hospital Heidelberg |
2020-03-01 |
| NCT03674411 |
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy |
https://ClinicalTrials.gov/show/NCT03674411 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-07-31 |
| NCT03629873 |
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects |
https://ClinicalTrials.gov/show/NCT03629873 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2019-08-01 |
| NCT03625037 |
GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03625037 |
Recruiting |
Genmab |
2022-01-30 |
| NCT03623373 |
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03623373 |
Active, not recruiting |
Washington University School of Medicine |
2020-02-09 |
| NCT03622788 |
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03622788 |
Recruiting |
M.D. Anderson Cancer Center |
2021-07-01 |
| NCT03601819 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT03601819 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-09-30 |
| NCT03585725 |
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03585725 |
Recruiting |
Weill Medical College of Cornell University |
2020-06-30 |
| NCT03571828 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03571828 |
Recruiting |
Amgen |
2023-06-30 |
| NCT03567876 |
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL |
https://ClinicalTrials.gov/show/NCT03567876 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2020-07-31 |
| NCT03547115 |
A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML |
https://ClinicalTrials.gov/show/NCT03547115 |
Recruiting |
MEI Pharma, Inc. |
2022-04-30 |
| NCT03505944 |
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03505944 |
Recruiting |
Nordic Lymphoma Group |
2020-12-01 |
| NCT03501576 |
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT03501576 |
Recruiting |
Emory University |
2021-04-30 |
| NCT03494179 |
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT03494179 |
Active, not recruiting |
Beijing InnoCare Pharma Tech Co., Ltd. |
2020-06-30 |
| NCT03478514 |
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03478514 |
Recruiting |
Alliance Foundation Trials, LLC. |
2022-06-30 |
| NCT03440567 |
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03440567 |
Recruiting |
City of Hope Medical Center |
2021-04-02 |
| NCT03424603 |
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT03424603 |
Recruiting |
Sutro Biopharma, Inc. |
2021-11-30 |
| NCT01267812 |
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01267812 |
Active, not recruiting |
City of Hope Medical Center |
2018-09-07 |
| NCT01263899 |
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01263899 |
Completed |
S*BIO |
2012-02-29 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01251575 |
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01251575 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-11-23 |
| NCT01239875 |
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01239875 |
Completed |
Mayo Clinic |
2015-11-24 |
| NCT01236391 |
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT01236391 |
Completed |
Pharmacyclics LLC. |
2014-01-31 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01231412 |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01231412 |
Completed |
Fred Hutchinson Cancer Research Center |
2016-10-08 |
| NCT01184885 |
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy |
https://ClinicalTrials.gov/show/NCT01184885 |
Completed |
Thomas Jefferson University |
2011-03-31 |
| NCT01181271 |
Tandem Auto-Allo Transplant for Lymphoma |
https://ClinicalTrials.gov/show/NCT01181271 |
Completed |
Massachusetts General Hospital |
2014-02-28 |
| NCT01180049 |
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01180049 |
Completed |
Pfizer |
2015-11-30 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT03872180 |
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03872180 |
Recruiting |
Emory University |
2021-04-30 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01148108 |
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01148108 |
Completed |
Telik |
2012-09-30 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01118845 |
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01118845 |
Completed |
SymBio Pharmaceuticals |
2011-10-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01109069 |
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01109069 |
Completed |
Pharmacyclics LLC. |
2019-04-26 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01088048 |
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01088048 |
Completed |
Gilead Sciences |
2015-04-30 |
| NCT01078142 |
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01078142 |
Completed |
Johannes Gutenberg University Mainz |
2017-09-08 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01073163 |
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT01073163 |
Completed |
Teva Pharmaceutical Industries |
2012-06-30 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01035463 |
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy |
https://ClinicalTrials.gov/show/NCT01035463 |
Completed |
University of Nebraska |
2017-07-27 |
| NCT01029366 |
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy |
https://ClinicalTrials.gov/show/NCT01029366 |
Completed |
University of Pennsylvania |
2015-07-31 |
| NCT00992992 |
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00992992 |
Completed |
GlaxoSmithKline |
2013-06-30 |
| NCT00992446 |
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00992446 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-06-17 |
| NCT00992134 |
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00992134 |
Completed |
St. Bortolo Hospital |
2011-06-30 |
| NCT00980395 |
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma |
https://ClinicalTrials.gov/show/NCT00980395 |
Completed |
University of Arizona |
2014-09-12 |
| NCT00963534 |
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. |
https://ClinicalTrials.gov/show/NCT00963534 |
Completed |
Lund University Hospital |
2017-08-31 |
| NCT00958256 |
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab |
https://ClinicalTrials.gov/show/NCT00958256 |
Completed |
M.D. Anderson Cancer Center |
2014-03-31 |
| NCT00921414 |
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance |
https://ClinicalTrials.gov/show/NCT00921414 |
Completed |
French Innovative Leukemia Organisation |
2008-09-30 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00901615 |
Lenalidomide and R-CHOP in B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00901615 |
Completed |
Lymphoma Study Association |
2010-11-19 |
| NCT00891839 |
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00891839 |
Completed |
Teva Pharmaceutical Industries |
2011-12-31 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00880815 |
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00880815 |
Completed |
M.D. Anderson Cancer Center |
2019-05-28 |
| NCT00878254 |
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00878254 |
Active, not recruiting |
University of Miami |
2021-09-30 |
| NCT00877214 |
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT00877214 |
Active, not recruiting |
University of Giessen |
2022-04-30 |
| NCT00877006 |
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study |
https://ClinicalTrials.gov/show/NCT00877006 |
Completed |
Teva Pharmaceutical Industries |
2012-03-31 |
| NCT00875667 |
A Study to Determine the Efficacy of Lenalidomide Versus Investigator’s Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT00875667 |
Completed |
Celgene |
2018-06-28 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00861510 |
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00861510 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-10-19 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00807495 |
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00807495 |
Completed |
Takeda |
2011-01-04 |
| NCT01686165 |
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL |
https://ClinicalTrials.gov/show/NCT01686165 |
Completed |
University of Arizona |
2016-02-09 |
| NCT01474681 |
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01474681 |
Completed |
Novartis |
2016-10-03 |
| NCT03523975 |
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03523975 |
Recruiting |
University of Michigan Rogel Cancer Center |
2020-07-31 |
| NCT03682796 |
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03682796 |
Recruiting |
Triphase Research and Development III Corp. |
2022-01-31 |
| NCT03185494 |
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 |
https://ClinicalTrials.gov/show/NCT03185494 |
Active, not recruiting |
Chinese PLA General Hospital |
2019-08-01 |
| NCT03147885 |
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03147885 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-06-30 |
| NCT03061188 |
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes |
https://ClinicalTrials.gov/show/NCT03061188 |
Active, not recruiting |
Northwestern University |
2020-09-30 |
| NCT02601313 |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02601313 |
Active, not recruiting |
Gilead Sciences |
2019-07-24 |
| NCT03616782 |
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) |
https://ClinicalTrials.gov/show/NCT03616782 |
Recruiting |
Kosin University Gospel Hospital |
2022-12-31 |
| NCT00875056 |
Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103) |
https://ClinicalTrials.gov/show/NCT00875056 |
Completed |
Merck Sharp & Dohme Corp. |
2011-02-25 |
| NCT00794638 |
A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00794638 |
Completed |
SymBio Pharmaceuticals |
2010-03-31 |
| NCT00791011 |
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat |
https://ClinicalTrials.gov/show/NCT00791011 |
Completed |
Amgen |
2010-07-31 |
| NCT00789776 |
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00789776 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-05-31 |
| NCT00787969 |
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00787969 |
Completed |
Alliance for Clinical Trials in Oncology |
2012-04-30 |
| NCT00786851 |
Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT00786851 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2010-07-31 |
| NCT00783367 |
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00783367 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2012-11-14 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00764517 |
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00764517 |
Completed |
OHSU Knight Cancer Institute |
2015-01-31 |
| NCT00740415 |
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00740415 |
Completed |
French Innovative Leukemia Organisation |
2011-05-31 |
| NCT00737529 |
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The “EMERGE” Trial |
https://ClinicalTrials.gov/show/NCT00737529 |
Completed |
Celgene |
2016-04-06 |
| NCT00723099 |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00723099 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-07-31 |
| NCT00722137 |
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00722137 |
Completed |
Takeda |
2014-01-01 |
| NCT00719888 |
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
https://ClinicalTrials.gov/show/NCT00719888 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-12-31 |
| NCT00711828 |
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00711828 |
Completed |
Mayo Clinic |
2013-11-30 |
| NCT00703664 |
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00703664 |
Completed |
National Cancer Institute (NCI) |
2017-12-01 |
| NCT00702052 |
Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy. |
https://ClinicalTrials.gov/show/NCT00702052 |
Completed |
Novartis |
2012-04-30 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00656084 |
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell |
https://ClinicalTrials.gov/show/NCT00656084 |
Completed |
US Oncology Research |
2007-01-31 |
| NCT00644189 |
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00644189 |
Active, not recruiting |
Massachusetts General Hospital |
2013-12-31 |
| NCT00641095 |
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00641095 |
Completed |
University College, London |
2011-11-23 |
| NCT00633594 |
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00633594 |
Completed |
SCRI Development Innovations, LLC |
2015-04-30 |
| NCT00621452 |
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00621452 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-01-31 |
| NCT00612183 |
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00612183 |
Completed |
SymBio Pharmaceuticals |
2009-09-30 |
| NCT00609869 |
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab |
https://ClinicalTrials.gov/show/NCT00609869 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2014-02-28 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00607854 |
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) |
https://ClinicalTrials.gov/show/NCT00607854 |
Completed |
University Hospital, Bordeaux |
2011-02-28 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00586755 |
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00586755 |
Completed |
Duke University |
2007-10-31 |
| NCT00581854 |
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00581854 |
Completed |
University of Wisconsin, Madison |
2006-06-30 |
| NCT00581776 |
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00581776 |
Completed |
University of Wisconsin, Madison |
2012-11-30 |
| NCT00571493 |
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00571493 |
Completed |
University of Nebraska |
2014-11-30 |
| NCT00553644 |
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00553644 |
Completed |
National Cancer Institute (NCI) |
2012-12-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00516412 |
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00516412 |
Completed |
Swiss Group for Clinical Cancer Research |
2010-01-31 |
| NCT00514475 |
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00514475 |
Completed |
Oslo University Hospital |
2009-06-30 |
| NCT00513955 |
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00513955 |
Completed |
University Hospital Plymouth NHS Trust |
2014-10-31 |
| NCT00505232 |
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) |
https://ClinicalTrials.gov/show/NCT00505232 |
Completed |
CABYC |
2010-03-31 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00490529 |
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL |
https://ClinicalTrials.gov/show/NCT00490529 |
Completed |
Stanford University |
2017-12-14 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00477412 |
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00477412 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-04-30 |
| NCT00472420 |
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. |
https://ClinicalTrials.gov/show/NCT00472420 |
Completed |
Hoffmann-La Roche |
2011-05-25 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00446342 |
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00446342 |
Completed |
Sunesis Pharmaceuticals |
2008-12-31 |
| NCT00445341 |
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00445341 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-04-30 |
| NCT00438880 |
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00438880 |
Completed |
Mayo Clinic |
2010-10-31 |
| NCT00433537 |
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00433537 |
Completed |
National Cancer Institute (NCI) |
2013-06-30 |
| NCT00420056 |
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. |
https://ClinicalTrials.gov/show/NCT00420056 |
Completed |
Pfizer |
2010-03-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00407303 |
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT00407303 |
Completed |
Teva Pharmaceutical Industries |
2009-03-31 |
| NCT00406809 |
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00406809 |
Completed |
AbbVie |
2016-10-31 |
| NCT00401817 |
Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00401817 |
Completed |
Weill Medical College of Cornell University |
2011-07-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00377052 |
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00377052 |
Completed |
Canadian Cancer Trials Group |
2009-04-21 |
| NCT00376961 |
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00376961 |
Completed |
Southwest Oncology Group |
2012-12-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00310037 |
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00310037 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2013-12-31 |
| NCT00294632 |
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00294632 |
Completed |
M.D. Anderson Cancer Center |
2016-02-29 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00285389 |
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years |
https://ClinicalTrials.gov/show/NCT00285389 |
Completed |
French Innovative Leukemia Organisation |
2005-12-31 |
| NCT00278382 |
Sorafenib in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00278382 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00275431 |
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies |
https://ClinicalTrials.gov/show/NCT00275431 |
Completed |
Ascenta Therapeutics |
2008-12-31 |
| NCT00275080 |
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00275080 |
Completed |
National Cancer Institute (NCI) |
2009-11-30 |
| NCT00253630 |
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00253630 |
Completed |
National Cancer Institute (NCI) |
2016-05-31 |
| NCT00234026 |
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00234026 |
Completed |
Swiss Group for Clinical Cancer Research |
2006-03-31 |
| NCT00225212 |
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00225212 |
Completed |
Stanford University |
2003-03-31 |
| NCT02840539 |
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02840539 |
Recruiting |
Seoul National University Hospital |
2020-02-29 |
| NCT00201877 |
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00201877 |
Completed |
Ohio State University Comprehensive Cancer Center |
2009-06-30 |
| NCT00186628 |
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD |
https://ClinicalTrials.gov/show/NCT00186628 |
Completed |
Stanford University |
2010-11-30 |
| NCT00151281 |
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00151281 |
Completed |
Weill Medical College of Cornell University |
2009-12-31 |
| NCT00119730 |
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00119730 |
Completed |
Dana-Farber Cancer Institute |
2006-12-31 |
| NCT00119392 |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00119392 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00118170 |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function |
https://ClinicalTrials.gov/show/NCT00118170 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00117988 |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00117988 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00117598 |
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) |
https://ClinicalTrials.gov/show/NCT00117598 |
Completed |
Pfizer |
2007-08-31 |
| NCT00114738 |
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00114738 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2016-08-11 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00110071 |
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00110071 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00109967 |
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00109967 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00109824 |
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00109824 |
Completed |
National Cancer Institute (NCI) |
2009-03-31 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00003039 |
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00003039 |
Completed |
National Cancer Institute (NCI) |
2000-04-30 |
| NCT00090090 |
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00090090 |
Completed |
Spectrum Pharmaceuticals, Inc |
NA |
| NCT00002879 |
Cladribine in Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00002879 |
Completed |
Alliance for Clinical Trials in Oncology |
2005-04-30 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00086944 |
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00086944 |
Completed |
National Cancer Institute (NCI) |
2006-07-31 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00082784 |
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT00082784 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00081874 |
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00081874 |
Completed |
M.D. Anderson Cancer Center |
2006-09-30 |
| NCT00003166 |
Bryostatin and Vincristine in B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT00003166 |
Completed |
National Cancer Institute (NCI) |
2001-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00003541 |
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00003541 |
Completed |
Memorial Sloan Kettering Cancer Center |
2006-07-31 |
| NCT00075478 |
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00075478 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-02-28 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00070447 |
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00070447 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00003280 |
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00003280 |
Completed |
Swiss Group for Clinical Cancer Research |
2002-03-31 |
| NCT00068315 |
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00068315 |
Completed |
National Cancer Institute (NCI) |
2008-12-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00063713 |
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00063713 |
Completed |
Millennium Pharmaceuticals, Inc. |
2005-12-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00060372 |
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
https://ClinicalTrials.gov/show/NCT00060372 |
Completed |
National Cancer Institute (NCI) |
2008-04-30 |
| NCT00003311 |
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00003311 |
Completed |
M.D. Anderson Cancer Center |
2007-04-18 |
| NCT00058305 |
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00058305 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00058227 |
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00058227 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00058019 |
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00058019 |
Completed |
National Cancer Institute (NCI) |
2010-08-31 |
| NCT00054639 |
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00054639 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00054483 |
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00054483 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00053092 |
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00053092 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00041132 |
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00041132 |
Completed |
Southwest Oncology Group |
2007-11-30 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00033267 |
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00033267 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00030875 |
Bortezomib in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00030875 |
Completed |
Canadian Cancer Trials Group |
2005-07-21 |
| NCT00026182 |
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00026182 |
Completed |
National Cancer Institute (NCI) |
2005-02-28 |
| NCT00025662 |
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS |
https://ClinicalTrials.gov/show/NCT00025662 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-02-29 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00020943 |
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00020943 |
Completed |
Alliance for Clinical Trials in Oncology |
2006-12-31 |
| NCT00017381 |
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00017381 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00016094 |
S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00016094 |
Completed |
National Cancer Institute (NCI) |
2005-08-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00010192 |
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00010192 |
Completed |
National Cancer Institute (NCI) |
2003-01-31 |
| NCT00006747 |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00006747 |
Completed |
Alliance for Clinical Trials in Oncology |
2003-02-28 |
| NCT00006473 |
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006473 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00005074 |
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00005074 |
Completed |
Canadian Cancer Trials Group |
2002-02-20 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00004231 |
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00004231 |
Completed |
Northwestern University |
2006-08-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00038623 |
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00038623 |
Completed |
M.D. Anderson Cancer Center |
2007-12-31 |
| NCT00450801 |
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00450801 |
Completed |
University of Miami |
2015-07-31 |
| NCT00022945 |
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00022945 |
Completed |
Corixa Corporation |
NA |
| NCT00023764 |
Bortezomib in Treating Patients With Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00023764 |
Completed |
National Cancer Institute (NCI) |
2009-03-31 |